Skip to main content

Advertisement

SpringerLink
Log in

Prostate Cancer Prevention: Concepts and Clinical Trials

  • Prostate Cancer (A Kibel, Section Editor)
  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Prevention is an important treatment strategy for diminishing prostate cancer morbidity and mortality and is applicable to both early- and late-stage disease. There are three basic classifications of cancer prevention: primary (prevention of incident disease), secondary (identification and treatment of preclinical disease), and tertiary (prevention of progression or recurrence). Based on level I evidence, 5-alpha reductase inhibitors (5-ARIs) should be considered in selected men to prevent incident prostate cancer. Level I evidence also supports the consideration of dutasteride, a 5-ARI, for tertiary prevention in active surveillance and biochemical recurrence patients. Vitamins and supplements, including selenium or vitamin E, have not been proven in clinical trials to prevent prostate cancer and in the case of Vitamin E has been found to increase the risk of incident prostate cancer. Ongoing and future trials may further elucidate the role of diet and immunotherapy for prevention of prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.

    Article  PubMed  Google Scholar 

  2. Tao ZQ, Shi AM, Wang KX, Zhang WD. Epidemiology of prostate cancer: current status. Eur Rev Med Pharmacol Sci. 2015;19(5):805–12.

    PubMed  Google Scholar 

  3. Punnen S, Cooperberg MR. The epidemiology of high-risk prostate cancer. Curr Opin Urol. 2013;23:331–6.

    Article  PubMed  Google Scholar 

  4. Moyer VA. U.S. Preventive Services Task Force. screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120–34.

    Article  PubMed  Google Scholar 

  5. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320–8.

    Article  PubMed  Google Scholar 

  6. Silberstein JL, Parsons JK. Prostate cancer prevention: concepts and clinical recommendations. Prostate Cancer Prostatic Dis. 2010;13(4):300–6.

    Article  CAS  PubMed  Google Scholar 

  7. Yamaguchi K, Uzzo RG, Pimkina J, Makhov P, Golovine K, Crispen P, et al. Methylseleninic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis. Oncogene. 2005;24:5868–77.

    Article  CAS  PubMed  Google Scholar 

  8. Lee SO, Yeon Chun J, Nadiminty N, Trump DL, Ip C, Dong Y, et al. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA). Prostate. 2006;66:1070–5.

    Article  CAS  PubMed  Google Scholar 

  9. van den Brandt PA, Zeegers MPA, Bode P, Goldbohm RA. Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2003;12:866–71.

    PubMed  Google Scholar 

  10. Duffield-Lillico AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, Jacobs ET, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int. 2003;91:608–12.

    Article  CAS  PubMed  Google Scholar 

  11. Chan JM, Stampfer MJ, Ma J, Rimm EB, Willett WC, Giovannucci EL. Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol Biomarkers Prev. 1999;8:893–9.

    CAS  PubMed  Google Scholar 

  12. Kirsh VA, Hayes RB, Mayne ST, Chatterjee N, Subar AF, Dixon LB, et al. Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. J Natl Cancer Inst. 2006;98:245–54.

    Article  CAS  PubMed  Google Scholar 

  13. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009;301:39–51. This was a phase III trial with over 35,000 men examining natural substances (selenium and vitamin E) for chemoprevention of prostate cancer. After 7 years of follow up, no significant benefit was seen for either substance. With additional follow up, there was a small but significantly increased risk of prostate cancer in the vitamin E group.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Klein EA, Thompson Jr IM, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306(14):1549–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Stevens VL, McCullough ML, Diver WR, et al. Use of multivitamins and prostate cancer mortality in a large cohort of US men. Cancer Causes Control. 2005;16(6):643–50.

    Article  PubMed  Google Scholar 

  16. Gaziano JM, Glynn RJ, Christen WG, Kurth T, Belanger C, MacFadyen J, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians’ Health Study II randomized controlled trial. JAMA. 2009;301:52–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Thomas LN, Douglas RC, Lazier CB, Too CK, Rittmaster RS, Tindall DJ. Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer. Eur Urol. 2008;53:244–52.

    Article  CAS  PubMed  Google Scholar 

  18. Rittmaster RS, Manning AP, Wright AS, Thomas LN, Whitefield S, Norman RW, et al. Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5 alpha-reductase inhibitor finasteride. Endocrinology. 1995;136:741–8.

    CAS  PubMed  Google Scholar 

  19. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215–24. This was a phase III trial evaluating the use of finasteride for prevention of prostate cancer over a 7 year follow up period. Over 18,000 men (at least 55 years old, PSA ≤ 3 ng/ml, normal DRE) were enrolled with for-cause biopsy or end-of-study biopsy performed. There was a 25 % relative risk reduction in prostate cancer detection associated with finasteride, although higher grade disease was diagnosed more frequently in the finasteride cohort.

    Article  CAS  PubMed  Google Scholar 

  20. Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007;99:1375–83.

    Article  CAS  PubMed  Google Scholar 

  21. Mellon JK. The finasteride Prostate Cancer Prevention Trial (PCPT) – what have we learned? Eur J Cancer. 2005;41:2016–22.

    Article  CAS  PubMed  Google Scholar 

  22. Wurzel R, Ray P, Major-Walker K, Shannon J, Rittmaster R. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2007;10:149–54.

    Article  CAS  PubMed  Google Scholar 

  23. Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362:1192–202. This was a phase III trial evaluating the use of dutasteride for prevention of prostate cancer over a 4 year period. 8000 men (50–75 years old, PSA 2.5–10 ng/ml, negative prostate biopsy within 6 months of enrollment) were screened every 6 months with for-cause biopsy or planned biopsy at 2 and 4 years performed. There was a 23 % relative risk reduction associated with dutasteride and an increased incidence of high grade disease in the dutasteride cohort. This confirmed the findings of the PCPT trial.

    Article  CAS  PubMed  Google Scholar 

  24. Lacy JM, Kyprianou N. A tale of two trials: the impact of 5α-reductase inhibition on prostate cancer (review). Oncol Lett. 2014;8(4):1391–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Theoret MR, Ning YM, Zhang JJ, Justice R, Keegan P, Pazdur R. The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention. N Engl J Med. 2011;365(2):97–9.

    Article  CAS  PubMed  Google Scholar 

  26. Kim J, Amos CI, Logothetis C. 5α-Reductase inhibitors for prostate-cancer prevention. N Engl J Med. 2011;365(24):2340.

    Article  CAS  PubMed  Google Scholar 

  27. Welch HG, Gorski DH, Albertsen PC. Trends in metastatic breast and prostate cancer-lessons in cancer dynamics. N Engl J Med. 2015;373(18):1685–7.

    Article  PubMed  Google Scholar 

  28. Jhaveri FM, Klein EA, Kupelian PA, Zippe C, Levin HS. Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. J Clin Oncol. 1999;17:3167–72.

    CAS  PubMed  Google Scholar 

  29. Etzioni R, Gulati R, Tsodikov A, et al. The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer. 2012;118(23):5955–63.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.

    Article  PubMed  Google Scholar 

  31. Carroll PR, Parsons JK, Andriole G, et al. Prostate cancer early detection, version 1.2014. featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2014;12(9):1211–9. quiz 1219.

    CAS  PubMed  Google Scholar 

  32. Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120–34.

    Article  PubMed  Google Scholar 

  33. Penson DF. The pendulum of prostate cancer screening. JAMA. 2015;314(19):2031–3.

    Article  PubMed  Google Scholar 

  34. Schröder FH, Hugosson J, Roobol MJ. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027–35.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Onc. 2010;11:725–32.

    Article  Google Scholar 

  36. Andriole GL, Crawford ED, Grubb RL, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104:125–32.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Grubb RL, Pinsky PF, Greenlee RT, et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int. 2008;102(11):1524–30.

    Article  PubMed  Google Scholar 

  39. Fleshner NE, Lucia MS, Egerdie B, et al. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet. 2012;379:1103–11. This phase III trial evaluated the use of dutasteride in an active surveillance cohort, enrolling 302 men with low risk prostate cancer and following them over a 3 year period with planned biopsies performed at 1.5 and 3 years. There was a 38 % relative risk reduction in pathologic and therapeutic progression in the dutasteride cohort, although it was unclear if this was due to a true medication effect or instead due to reductions in patient/provider treatment anxiety given that dutasteride lowers PSA values and improves PSA operating characteristics.

    Article  CAS  PubMed  Google Scholar 

  40. Thompson IM, Chi C, Ankerst DP, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst. 2006;98:1128–33.

    Article  CAS  PubMed  Google Scholar 

  41. Latini DM, Hart SL, Knight SJ, et al. The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol. 2007;178(3 Pt 1):826–31. discussion 831-2.

    Article  PubMed  Google Scholar 

  42. Schröder F, Bangma C, Angulo JC, et al. Dutasteride treatment over 2 years delays prostate-specific antigen progression in patients with biochemical failure after radical therapy for prostate cancer: results from the randomised, placebo-controlled Avodart After Radical Therapy for Prostate Cancer Study (ARTS). Eur Urol. 2013;63(5):779–87.

    Article  PubMed  Google Scholar 

  43. Ehdaie B, Touijer KA. 5-alpha Reductase inhibitors in prostate cancer: from clinical trials to clinical practice. Eur Urol. 2013;63(5):788–9. discussion 790-1.

    Article  PubMed  Google Scholar 

  44. Parsons JK, Pierce JP, Mohler J, et al. A randomized trial of diet in men with early stage prostate cancer on active surveillance: rationale and design of the Men’s Eating and Living (MEAL) Study. Contemp Clin Trials. 2014;38(2):198–203.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Geary SM, Salem AK. Prostate cancer vaccines: update on clinical development. Oncoimmunology. 2013;2(5):e24523.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115(16):3670–9.

    Article  CAS  PubMed  Google Scholar 

  47. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–22.

    Article  CAS  PubMed  Google Scholar 

  48. Gulley JL, Heery CR, Madan RA, et al. Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer. Cancer Immunol Immunother. 2013;62(9):1521–31.

    Article  CAS  PubMed  Google Scholar 

  49. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28(7):1099–105.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Sartor O, Gomella LG, Gagnier P, Melich K, Dann R. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design. Can J Urol. 2009;16(5):4806–12.

    PubMed  Google Scholar 

  51. Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess. 2007;11:1–160.

    Google Scholar 

  52. Hoque A, Chen H, Xu XC. Statin induces apoptosis and cell growth arrest in prostate cancer cells. Cancer Epidemiol, Biomarkers Prevent: Public Am Assoc Cancer Res, Cosponsored Am Soc Prevent Oncol. 2008;17:88–94.

    Article  CAS  Google Scholar 

  53. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest. 2005;115:959–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Bansal D, Undela K, D’Cruz S, Schifano F. Statin use and risk of prostate cancer: a meta-analysis of observational studies. PLoS One. 2012;7:e46691.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Agalliu I, Salinas CA, Hansten PD, Ostrander EA, Stanford JL. Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol. 2008;168:250–60.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Platz EA, Tangen CM, Goodman PJ, et al. Statin drug use is not associated with prostate cancer risk in men who are regular screened. Urology. 2014;192(2):379–84.

    Article  CAS  Google Scholar 

  57. Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB. The role of inflammation in the pathogenesis of prostate cancer. J Urol. 2004;172:S6–11. discussion S11-12.

    Article  CAS  PubMed  Google Scholar 

  58. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med. 2003;349:366–81.

    Article  CAS  PubMed  Google Scholar 

  59. Choe KS, Cowan JE, Chan JM, Carroll PR, D’Amico AV, Liauw SL. Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol. 2012;30:3540–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Jacobs EJ, Rodriguez C, Mondul AM, Connell CJ, Henley SJ, Calle EE, et al. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst. 2005;97:975–80.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Moores Comprehensive Cancer Center, UC San Diego Health System, 3855 Health Sciences Drive, Mail Code: 0987, La Jolla, CA, 93093-0987, USA

    Zachary Hamilton & J. Kellogg Parsons

Authors
  1. Zachary Hamilton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Kellogg Parsons
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Kellogg Parsons.

Ethics declarations

Conflict of Interest

Zachary Hamilton and J. Kellogg Parsons each declare no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Prostate Cancer

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hamilton, Z., Parsons, J.K. Prostate Cancer Prevention: Concepts and Clinical Trials. Curr Urol Rep 17, 35 (2016). https://doi.org/10.1007/s11934-016-0587-1

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11934-016-0587-1

Keywords

Search

Navigation